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Summary
Objective: Insulin-like growth factor-I (IGF-I) is critically involved in the control of cartilage matrix metabolism. It is well known that IGF-binding
protein-3 (IGFBP-3) is increased during osteoarthritis (OA), but its function(s) is not known. In other cells, IGFBP-3 can regulate IGF-I action in
the extracellular environment and can also act independently inside the cell; this includes transcriptional gene control in the nucleus. These
studies were undertaken to localize IGFBP-3 in human articular cartilage, particularly within cells.
Design: Cartilage was dissected from human femoral heads derived from arthroplasty for OA, and OA grade assessed by histology. Tissue
slices were further characterized by extraction and assay of IGFBPs by IGF ligand blot (LB) and by enzyme-linked immunosorbent assay
(ELISA). Immunohistochemistry (IHC) for IGF-I and IGFBP-3 was performed on cartilage from donors with mild, moderate and severe OA.
Indirect ﬂuorescence and immunogold-labeling IHC studies were included.
Results: LBs of chondrocyte lysates showed a strong signal for IGFBP-3. IHC of femoral cartilage sections at all OA stages showed IGF-I and
IGFBP-3 matrix stain particularly in the top zones, and closely associated with most cells. A prominent perinuclear/nuclear IGFBP-3 signal was
seen. Controls using non-immune sera or antigen-blocked antibody showed negative or strongly reduced stain. In frozen sections of human ankle
cartilage, immunoﬂuorescent IGFBP-3stainco-localizedwith thenuclear40,6-diamidino-2-phenyl indole (DAPI) stain ingreater than90%of thecells.
Immunogold IHC of thin sections and transmission electron immunogold microscopy of ultra-thin sections showed distinct intra-nuclear staining.
Conclusions: IGFBP-3 in human cartilage is located in the matrix and within chondrocytes in the cytoplasm and nuclei. This new ﬁnding
indicates that the range of IGFBP-3 actions in articular cartilage is likely to include IGF-independent roles and opens the door to studies of
its nuclear actions, including the possible regulation of hormone receptors or transcriptional complexes to control gene action.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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The insulin-like growth factor (IGF) signaling axis is involved
in the maintenance of matrix metabolism in articular carti-
lage1,2. Degenerative arthritis (osteoarthritis (OA)) is hall-
marked by a demise in the metabolic control of cartilage
matrix content3 and therefore, possible aberrations in the
IGF signaling system prior to or during OA are of great inter-
est. It is well known that IGF activities are regulated by the
high afﬁnity IGF-binding proteins (IGFBPs), a system of six
homologous proteins encoded by different genes4,5. The
IGFBPs are a highly versatile group of proteinswith the ability
to inhibit or enhance IGF action depending on tissue speciﬁc
regulation. Several investigators have demonstrated in-
creased IGFBPs, primarily IGFBP-3 in chondrocytes derived1Supported by: National Institute of Arthritis, Musculoskeletal and
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185from OA patients compared to normal controls6,7 and in car-
tilage explant cultures8. In addition, others andwe have dem-
onstrated that elevated levels of IGFBP-3 can be directly
extracted or desorbed from fresh uncultured cartilages of
OA vs normal donors9,10. More recently, a weak but statisti-
cally signiﬁcant correlation of IGFBP-3 levels vs OA score
was found in a group of 35 samples from various OA
stages11. Previously, IGFBP-3 was co-localized with ﬁbro-
nectin in the pericellular matrix of the chondrocyte12. This
pool of IGFBP-3 may be involved in the modulation of IGF-I
activity in the vicinity of the IGF-I signaling receptors4,5.
Interestingly, several of the IGFBPs are also capable of
signaling independently of the IGFs presumably through
their own cellular receptors13, and/or by direct nuclear inter-
actions14. Consistent with these ﬁndings, recent studies
have suggested that IGFBP-3 may also have IGF-indepen-
dent actions in cartilage. Transgenic mice overexpressing
IGFBP-3 show retarded growth, even though they have in-
creased serum IGF-I levels15. This may be due to a direct
action of IGFBP-3 at the level of the growth plate. Further,
studies with a chondrogenic cell line (RCJ3.1C5.18) reveal
that IGFBP-3 has anti-proliferative actions in chondroproge-
nitors and early chondrocytes derived from this cell line.
This activity is independent of IGF-I and involves activation
186 E. B. Hunziker et al.: Cellular IGFBP-3 in human cartilageof the signal transducer and activator of transcription-1
(STAT-1)16. These studies opened the question of whether
IGFBP-3 also has independent actions within articular
cartilage. We now explore the localization of IGFBP-3 in
human cartilages, focusing on its intra-cellular distribution
and providing new insights into the likely range of action
of IGFBP-3 in health and disease.Materials and methodsTISSUE SOURCES AND PREPARATIONFig. 1. 125IGF-II Western LBs of cell lysates compared to total tissue
extracts. Sample 10-04 D was divided into two portions; one was
extracted (Methods) and the second was subjected to proteolytic di-
gestion to isolate chondrocytes, which were then lysed by RIPA
buffer (Methods). Sample 11-04D was used for isolation and lysis
of chondrocytes in the same manner. Twenty-ﬁve micrograms of
tissue extract or cell lysate protein were applied per well. IGF LB
was as described9. The IGFBPs were identiﬁed by their molecular
weight and previous immunological identiﬁcation9. BP3¼ IGFBP-3,
BP2 ¼ IGFBP-2, and BP4 ¼ IGFBP-4. The histological Mankin
scores for the samples (from left to right) were: 8.5, 8.5, and N.D.
(not determined), 7.5, 3, and 7.5.Human cartilages were obtained as discarded surgical
material (under Massachusetts General Hospital (MGH)
protocol #000214 for human subjects research). Tissues in-
cluded the femoral heads of ﬁve donors who underwent hip
arthroplasty for OA (ages 45e55 years; one female and four
males) and one 70-year-old female donor who underwent
knee arthroplasty for OA. For each source that had a deﬁned
ulcer and sufﬁcient cartilage left on the joint, two pools of car-
tilage slices were prepared: ﬁbrillated and non-ﬁbrillated (to
the naked eye). The ﬁbrillated cartilage was obtained mostly
from the rim of the ulcer, comprising w3e4 mm of the sur-
rounding tissue. The unﬁbrillated cartilage was obtained
mostly from sites distal to the ulcer, and included smooth
and superﬁcially ﬁbrillated cartilage. Two to three slices
from each site were used for histological assessment of
OA grade by the Mankin method17. This method scores se-
verity of disease by evaluation of tissue integrity (formation
of ﬁssures and clefts), cell numbers and clone formation,
and proteoglycan matrix levels (safranine-O stain). The in-
tegrity of the tidemark was not evaluated in this study. The
best score obtained with this method is 0 (normal) and the
worst is 13 (most severe OA). One blinded evaluator and
one unblinded author (TIM) scored the samples; the grades
were averaged. Additionally, three representative slices
from each cartilage pool were removed for immunohisto-
chemistry (IHC). Both sets of slices were immediately
immersed in cold 4% formaldehyde and ﬁxed overnight at
4C. The remainder of the cartilage slices were processed
for biochemistry as previously described9, i.e., they were
extracted in 8 M urea containing buffer, the proteoglycans
removed by diethylaminoethyl (DEAE) chromatography and
the eluted proteins dialyzed and dried by speed vac centrifu-
gation. The buffers used for extraction and chromatography
were also enriched in proteinase inhibitors to help protect
IGFBP-3 from degradation (5 mM phenylmethylsulfonyl
ﬂuoride (PMSF), 3 mM o-phenanthroline (o-phe), 6.5 mM
pepstatin and 9.5 mM leupeptin); these inhibitors were also
maintained in acidic (4 mM HCl) solutions during the exten-
sive dialysis prior to drying9 (0.1 mM PMSF, 1 mM o-phe,
0.15 mM pepstatin and 0.2 mM leupeptin). Aliquots were re-
suspended in assay buffer and IGFBP-3 was measured by
enzyme-linked immunosorbent assay (Diagnostic Systems
Laboratories). The Iowa team (JM and JB) also obtained
human cartilage from their operating room (the University
of Iowa protocol #200502797). Ankle cartilage was obtained
from a 19-year-old female donor who underwent an above-
knee amputation as treatment for osteosarcoma and used
for the immunoﬂuorescence study. Additional tissue from
the knee of a 48-year-old male, derived from an arthroplasty
for OA, was obtained at MGH, and tissue slices were
immersed in Dulbecco’s modiﬁed Eagle medium:nutrient
mix F-12 (containing penicillin, streptomycin and Hepes
buffer) and sent to Iowa by overnight FEDEX. This tissue
was used for preparation of thin sections for immunogold
IHC and transmission electron microscopy (TEM).IHC OF FEMORAL HEAD SPECIMENSAfter overnight ﬁxation in cold 4% formaldehyde, the
cartilage samples were embedded in parafﬁn blocks as
previously described. After scoring the OA stage in parallel
sections17 of the same donors and sites, parafﬁn embed-
ded slices from three sites representing mild, moderate
and severe OA were selected for IHC (54-year-old male,
45-year-old female and 55-year-old male, respectively).
The blocks were then shipped via priority international car-
rier (FEDEX) to Dr Hunziker’s laboratory in Switzerland.
Sections were cut to a thickness of 5 mm and then sub-
jected to treatment with chondroitinase ABC (0.02 U/ml)
for 60 min. The standard horseradish peroxidase immuno-
histochemical protocol of Sternberger and Sternberger18
was followed. Brieﬂy, unspeciﬁc epitopes in the cartilage
sections were blocked by treatment with 1% bovine serum
albumin (BSA) for 45 min prior to the immune reaction.
Samples were immunoreactive at 1:100e1:200 dilution of
anti-human IGFBP-3 (Upstate Biotechnologies). Immune
reaction with the IGFBP-3 antibody was monitored by
addition of the secondary antibodyeperoxidase complex
and measurement of peroxidase activity with the 3-
amino-9-ethylcarbazole substrate. Sections were counter-
stained with Meyer’s hematoxylin at a dilution of 1:5 for
1 min. Negative controls were prepared for all samples;
these included (1) samples treated with non-immune
serum instead of the ﬁrst antibody (anti-IGFBP-3), and
(2) samples treated with anti-IGFBP-3 previously blocked
by incubation with excess antigen (12:1 molar ratio) and
187Osteoarthritis and Cartilage Vol. 16, No. 2then diluted 1:200. IHC for IGF-I was similarly performed in
sections from the same donors using polyclonal anti-IGF-I
from GroPep Ltd. Signal visualization required a 1:20
antibody dilution. The antigen-blocked controls were also
performed with a 1:20 dilution of the antigeneantibody
complex.FROZEN SECTIONSCartilage cryosections (10 mm-thick) were ﬁxed for 5 min
in freshly prepared 2% paraformaldehyde. Sections were
washed in phosphate buffered saline with 0.3% Tween-20
(PBST) and blocked for 1 h in PBST with 1.0% BSA. Sec-
tions were incubated overnight at 4C in rabbit polyclonal
anti-IGFBP-3 primary antibody (diluted 1:250 in PBST, 1%
BSA). After three washes in PBST the sections were
blocked for 30 min with PBST containing 10% normal goat
serum. The sections were then incubated for 1 h at room
temperature with a goat anti-rabbit Cy2-conjugated second-
ary antibody (Jackson Immunoresearch), which was diluted
1:250 in PBSTþ 10% goat serum. After several washes in
PBST the sections were mounted in Vectashield (Vector
Laboratories) containing 40,6-diamidino-2-phenyl indole
(DAPI). Stained sections were imaged on an Olympus
BX60 epiﬂuorescence microscope using 488 nm illumina-
tion for Cy2 and 390 nm illumination for DAPI. One section
was used as a negative control (no primary antibody).SAMPLE PROCESSING FOR LIGHT AND TRANSMISSION
ELECTRON MICROSCOPYPieces of human knee cartilage were ﬁxed overnight in
2% paraformaldehyde (Electron Microscopy Sciences,
Hatﬁeld, PA) in phosphate buffered saline pH 7.2
(PBS), rinsed in PBS and dehydrated in a graded ethanol
series. Samples were inﬁltrated with several changes of
London Resin White resin (Ted Pella Inc., Redding,Fig. 2. IHC for IGFBP-3 of samples with normal and intermediate stage OA
The superﬁcial zone is facing the top of the ﬁgure and approximately the to
from a donor with intermediate grade OA (Mankin grade 6). The photo in C
middle section. Magniﬁcation is w200. Sections were counterstaCA). The pieces were then placed in ﬂat embedment
molds, covered in Aclar to minimize exposure to air and
polymerized overnight with ultraviolet light. The resulting
blocks were sectioned at 1 mm using a diamond histology
knife (Diatome, Biel, Switzerland) and collected upon pre-
cleaned glass slides. Ultra-thin sections for TEM (90 nm)
were cut using an ultra-diamond knife (Diatome; Biel,
Switzerland) on a Leica UC-6 ultramicrotome (Leica Mi-
crosystems GmbH, Ernst-Leitz-Strasse 17-37).IHC OF THIN SECTIONSA Pelco Biowave, a laboratory microwave (Ted Pella Inc.,
Redding, CA) was set to a temperature restriction of 37C at
150 W of power. Slides were placed directly on a Cold-Spot
load cooler (Ted Pella Inc., Redding, CA). The sections on
the slides were covered in PBST (Dulbecco’s PBS adjusted
to pH 7.4; with 0.1% Tween-20) and given 30 s of microwave
power. The solution was drained and replaced with 0.05 M
glycine in PBST and given another 30 s of microwave
power. After three 5 min rinses in PBS at room temperature,
the sections were covered in an incubation solution of PBST
containing 1% acetylated BSA (Electron Microscopy Sci-
ences, Hatﬁeld, PA), and 0.1% cold water ﬁsh skin gelatin
(Electron Microscopy Sciences, Hatﬁeld, PA) and micro-
waved for 30 s. IGFBP-3 antibody was diluted in a 1:200
concentration in the incubation buffer or incubation solution
alone and micro-waved for 30 s, allowed to rest for 30 s, and
micro-waved for another 30 s. The slides were rinsed in
three changes of PBST and a solution of goat anti-rabbit ul-
tra-small gold conjugate (Aurion, The Netherlands) was
ﬂooded onto the sections in a 1:75 concentration in incuba-
tion buffer and micro-waved in the same manner as the pri-
mary. The slides were again rinsed in PBST at room
temperature three times, rinsed in double distilled water
and silver enhanced with AURION R-Gent Silver Enhance-
ment Kit (Electron Microscopy Sciences, Hatﬁeld, PA) for. Panels A and B show slices from a normal donor (Mankin grade 1).
p half of the cartilage section is shown. Panels C and D show tissue
shows approximately the lower 2/3 of the section, and D shows the
ined with Meyer’s hematoxylin at a dilution of 1:5 for 1 min.
188 E. B. Hunziker et al.: Cellular IGFBP-3 in human cartilage18 min. The slides were viewed with a BX-51 Olympus light
microscope in both brightﬁeld and darkﬁeld modes.TRANSMISSION ELECTRON MICROSCOPYThe ultra-thin sections were placed onto a 2 1 slot grid
coated with a thin layer of formvar. Immunocytochemistry
was performed as above with the sections ﬂoating onFig. 3. IHC for IGFBP-3 of samples with advanced OA. Panels A and B s
a control of the same cartilage treated with antigen-blocked primary antib
which the primary antibody was omitted. Full cartilage depth is shown in
is w200a 20 ml drop of reagent. Grids were then examined with
a JEOL-1230 Transmission Electron Microscope (1-2,
Musashino 3-chome Akishima, Tokyo 196-8558, Japan).IGF LIGAND BLOTSFor comparison of cell lysates and tissue extracts, a sam-
ple (coded 10-04D) was divided such that half of the cartilagehow cartilage from a donor with a Mankin grade 9. Panel C shows
ody (AG:AB molar ratio¼ 12:1), and D shows a second control in
the sections, which were counterstained as in Fig. 2. Magniﬁcation
.
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hibitors and puriﬁed by the methods described before9 (sum-
marized above); the other half of the cartilage was subjected
to digestion with pronase and collagenase to release cells19.
Another sample (coded 11-04D; from knee cartilage) was
used only for cell preparation. Isolated chondrocytes were
maintained in spinner culture overnight20 and then lysed
with RIPA lysis buffer (0.05 M TriseHCl, pH 7.4, 0.15 M
NaCl, 0.25% deoxycholic acid, 1% NP-40 and 1 mM [ethyl-
ene diamine tetra-acetic acid] EDTA) fromUpstate. The lysis
buffer was supplemented with additional proteinase inhibi-
tors (1 mM PMSF, 1 mg/ml each of aprotinin, leupeptin and
pepstatin) and with phosphatase inhibitors (1 mM sodium
orthovanadate and 1 mM sodium ﬂuoride).Results
In previous work, the correlation of IGFBP-3 levels with
OA was examined closely by determining the relationship
between levels of the binding protein and individual OA
scores11. It could be demonstrated that while the relation-
ship was weak, there was a statistically signiﬁcant correla-
tion between IGFBP-3 and OA score. There was also
a molar dominance of IGF-I over IGFBP-3 in many of the
OA samples, irrespective of score11. This led us to ask
whether different sub-anatomical pools contain high pockets
of IGFBP-3 that may be diluted or obscured in the tissue ex-
tracts, but which may play different roles during OA.
Since there are a number of reports indicating that
IGFBP-3 is found within the cell in various cell lines, the
question of whether some of the IGFBP-3 is present in
chondrocytes was raised. We ﬁrst addressed this question
by preparing fresh chondrocytes and lysing them after min-
imal culture (overnight in spinner culture). This short incu-
bation period was designed to allow cell recovery from
proteolytic matrix excision, while minimizing pericellularFig. 4. IHC of nuclei for IGFBP-3 in normal cartilage. Panels A, B and
IGFBP-3. Panel A shows the approximate upper third, panel B shows an
panel C shows the approximate lower third of cartilage (deep zone). Ant
in Fig. 2. Magniﬁcation is approximately 600. The right hand inset in pan
angle in this inset shows the approximate locatprotein accumulation. Figure 1 shows an IGF ligand blot
(LB) in which chondrocyte lysates were run alongside
cartilage extracts and the membranes probed with a
125I-IGF-II ligand. It can be clearly seen that the cell lysates
displayed a very strong positive signal coincident with
IGFBP-3. The cell lysate of the 10-04D sample can be di-
rectly compared to the tissue extract from the same sample
(Fig. 1): the lysate showed a much stronger signal even
though equal amounts of protein were added to each
lane. The more extensive dilution of the whole tissue
extracts with matrix protein may have contributed to this.
However, the ﬁnding that both cell lysates displayed strong
signals for IGFBP-3 was consistent with the possibility that
a signiﬁcant portion of the IGFBP-3 in cartilage was cell-as-
sociated. We then needed to rule out the possibility that cel-
lular expression was a consequence of the preparative
procedures (release of chondrocytes from the matrix by
proteolysis) and/or the short incubation period of the cells
prior to lysis.
To explore the cellular localization of IGFBP-3 in intact
cartilage we carried out IHC of representative slices from
normal human cartilage (Normal, Mankin grade 1; IGFBP-3
content¼ 6 ng/mg protein), from intermediate (score 6;
15 ng IGFBP-3/mg protein) and advanced OA grades
(score 9; 17 ng IGFBP-3/mg protein). Figure 2 clearly
shows the presence of cell-associated IGFBP-3 in slices
of normal human cartilage (panels A and B) and in sections
of cartilage from a donor with intermediate OA (panels C
and D). In addition, Fig. 3(A and B) shows that cartilage
from a donor with severe OA also shows strong cellular im-
munostain, which includes the cloned cells. Matrix stain
was noted in all sections. In the normal cartilage, staining
was seen as a thin layer on the top zone of the section
[Figs. 2(A and B) and 4(A)]. In the OA samples, there was
more staining, which extended deeper into the section
[Figs. 2(C) and 3(A and B)] but remained mostly conﬁned
to approximately the top half of the section.C show the normal cartilage (Mankin grade 1) immunostained for
other view of a similar section just under the superﬁcial zone and
ibody was used at 1:100 dilution. Sections were counterstained as
el C shows the full-depth section, stained with safranine-O; the rect-
ion of the IHC section shown in panel C.
190 E. B. Hunziker et al.: Cellular IGFBP-3 in human cartilageIn all samples at all OA stages, >90% of the cells were
clearly positive for IGFBP-3 content. Importantly, many of
the cells in all samples had a strong nuclear IGFBP-3 sig-
nal. This can be appreciated best in high-resolution photo-
graphs of normal cartilage shown in Fig. 4(A and B),
which show intense but discreet immunoreactivity associ-
ated with the nucleus. In addition, many of the cells had
a web-like IGFBP-3 pattern outside of the nucleus
[Fig. 4(A and B)]. Chondrocytes in the deep zone of the nor-
mal cartilage specimens were negative while the OA sam-
ples showed a positive cellular signal in this zone
[compare Fig. 4(C) to Fig. 3(A and B)]. Controls were pre-
pared for each of the samples either without anti-IGFBP-3
or with anti-IGFBP-3 previously saturated with IGFBP-3 an-
tigen. The negative antibody controls were negative for cells
in all the samples [see Fig. 3(D) for example], and the anti-
gen-blocked antibody controls consistently showed very re-
duced cell immunoreactivity [e.g., Fig. 3(C)]. The matrix
stain was also blocked or largely reduced in all control sam-
ples. However, it needs to be pointed out that theFig. 5. Immunohistochemical staining for IGF-I. Panel A shows a normal c
are intermediate OA samples, with D being the minus antibody negative co
is a full section of very thin residual cartilage in this severe OA sample,
stained as described in the legend to Fig. 2. Magniﬁcationintermediate OA sample [Fig. 2(C)] had particularly intense
matrix stain in the top zone [partially shown in the top of
Fig. 2(C)] and diffuse stain remained in the antigen-blocked
controls (not shown).
We then asked whether the IGF-I ligand showed a similar
distribution in sections from the same samples examined by
IGFBP-3 IHC. Figure 5 shows the close association of IGF-I
with the chondrocyte in the normal (panel A) and severe OA
(panel B) cartilages. Panel C shows a fuller view of the car-
tilage with intermediate OA; there is more intense IGF-I
stain in the upper half of the cartilage in both cells and ma-
trix. This general distribution pattern was also observed in
the normal and severe OA samples. Panel D shows the
negative control performed without antibody with greatly di-
minished stain in both the matrix and the cell compartments.
Similarly, antigen-blocked controls showed greatly reduced
immunostain. In contrast to the IGFBP-3 distribution, IGF-I
did not show a dominant association with the nucleus.
The apparent nuclear localization of IGFBP-3 deserved
closer scrutiny. Frozen sections of 19-year-old humanartilage, panel B shows a severe OA cartilage and panels C and D
ntrol. Panel A shows the approximate upper third of the cartilage, B
and panels C and D are full-depth ﬁgures. Sections were counter-
is 400 for panels A and B and 200 for C and D.
191Osteoarthritis and Cartilage Vol. 16, No. 2cartilage from an ankle joint were examined. Figure 6 shows
the immunoﬂuorescent IGFBP-3 stain in the left side panels
(A and C) and the DAPI stain in the right side panels (B and
D) for adjacent sections. The coincidence between the
staining patterns can be seen, indicative of immunoreactive
IGFBP-3 in association with the nucleus. Figure 6(E) shows
the overlay of the two images from panels C and D.Fig. 6. Fluorescent immunomicroscopy of IGFBP-3 and DAPI stained nuc
rescent stain for IGFBP-3 detected with Upstate anti-IGFBP-3 (1:250 d
(Jackson Immunoresearch). Panels B and D show adjacent sections sta
panels C and D demonstrating co-localizExtranuclear stain can also be appreciated. Negative con-
trols (without primary antibody) were blank (not shown).
We then prepared thin sections and used immunogold-
labeling techniques in order to ascertain if the immunoreac-
tivity associated with the nucleus was intra-nuclear. The
tissue source for these studies was a human knee from
an OA arthroplasty; the histological OA grade (7.5)lei in young human cartilage. Panels A and C show the orange ﬂuo-
ilution) and a Cy2-conjugated goat anti-rabbit secondary antibody
ined with DAPI to reveal the nuclei. Panel E shows an overlay of
ation of IGFBP-3 and DAPI stain.
Fig. 7. Immunogold and immunohistochemical staining on thin sections of human cartilage. Panels A through D show light micrographs of
1 mm sections. Panels A and C show staining of nuclei in chondrocytes (arrows) in the transitional zone and in the superﬁcial zone, respec-
tively. Panels B and D show negative controls (without antibody). Panel E shows intra-nuclear immunogold labeling (arrow) for IGFBP-3 in
a transitional zone chondrocyte imaged by TEM.
192 E. B. Hunziker et al.: Cellular IGFBP-3 in human cartilageindicated that this was an intermediate-to-severe OA sam-
ple. Figure 7(A and C) shows thin sections (1 mm) of chon-
drocytes with stained nuclei (arrows) in the transitional zone
and the superﬁcial zone, respectively, examined by light mi-
croscopy. Figure 7(E) shows the immunogold TEM, which
further supports the intra-nuclear location of IGFBP-3.Discussion
The possibility that the IGF-I axis members are segre-
gated within tissue and sub-cellular compartments was con-
sidered. Tardif et al.7 had observed that lysates from
monolayer-cultured chondrocytes contained IGFBP-3. We
decided to examine freshly isolated chondrocytes main-
tained in suspension culture for a short overnight period
to minimize cellular changes from culture conditions. These
experiments indicated that human chondrocyte lysates con-
tained signiﬁcant levels of IGFBP-3, as assessed by IGF LB
analysis. We next examined the presence of cell-associ-
ated IGFBP-3 in intact cartilage slices representing mild, in-
termediate and severe OA stages by IHC. Positive cellular
stain was observed with IGFBP-3 antibodies. A previous re-
port of IHC in human cartilage showed low-resolution immu-
nostaining of IGFBP-3 that seemed associated with cells
and matrix21. Our studies extend these previous observa-
tions by showing high-resolution microscopy and presenting
results of two types of negative controls. As a result, we
were able to detect immunoreactive IGFBP-3 in the nu-
cleus. This ﬁnding was veriﬁed and extended by (1) immu-
noﬂuorescent co-localization of IGFBP-3 stain and nuclear
DAPI stain in frozen sections, (2) immunogold label light
microscopy of thin sections and (3) immunogold TEM.
The nuclear localization of IGFBP-3 is a new ﬁnding in
chondrocyte biology, and our study presents one of the
most comprehensive evaluations of the association of this
protein with the nucleus of any primary cell type. A related
paper authored by one of us (TIM) describes the sub-cellu-
lar fractionation of bovine chondrocytes (Sun et al., in prep-
aration). In this work, we prepared enriched cytoplasmicand nuclear fractions and characterized them by protein
patterns, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), histone and DNA localization, as well as by mi-
croscopy of the isolated nuclei. We observed immunoreac-
tive IGFBP-3 in both the cytoplasmic and nuclear fractions.
These ﬁndings complement and extend the present work by
using a completely independent approach to demonstrate
the presence of IGFBP-3 in the nuclei of chondrocytes
from another species.
The IGFBP-3 immunostain observed in the matrix in the
upper zone of many sections was blocked in most of the
controls but diffuse residual stain remained in some sec-
tions, particularly in the more intensely stained intermediate
OA cartilage. Thus, the largest fraction of the immunostain-
ing reaction was of a speciﬁc nature, but there was a small
non-speciﬁc component to the (interterritorial) matrix stain in
the top cartilage zones. It is likely that matrix IGFBP-3 in this
top zone of cartilage is derived from diffusion from synovial
ﬂuid22. This later statement is consistent with the work of
Schneiderman et al.22, who carried out a study in which
IGF-I and its complexes were desorbed from the superﬁcial
(top 200 mm) vs middle to deep zones of human articular
cartilage, using ﬁve normal and nine OA samples. These
authors showed a dominance of IGF-I and its IGFBP com-
plexes in the superﬁcial zone vs the middle and deep zones
of normal and OA human cartilages, with higher levels in
the OA cartilage. Of particular interest was their ﬁnding of
large complexes composed of the IGF ligand, the IGFBP
and the serum acid-labile subunit ALS molecule in OA car-
tilage, with ﬁve-fold more of the complex in the superﬁcial
zone vs the middleedeep zones. This large complex was
not detectable in normal cartilage. Their IGF LB also shows
IGFBP-3 mostly in the top zones of OA cartilage. In its ma-
trix localization, IGFBP-3 may present a diffusion barrier to
IGF-I and limit its access to signaling receptors. Consistent
with this general view, a previous study of IGF-I transport
through bovine cartilage indicated that IGF-I diffusion is
impeded by IGFBPs23. Sequestered IGF-I may then be
released upon demand. Our present ﬁndings that the IGF-I
ligand is present in the matrix of the top OA cartilage zones,
193Osteoarthritis and Cartilage Vol. 16, No. 2and is closely associated with the chondrocyte, are consis-
tent with this view.
Taken together, our previous and current data suggest
the following novel hypothesis. The tissue segregation of
IGFBP-3 may reﬂect different loci of activity: (1) matrix-as-
sociated IGFBP-3 may be involved in the control of IGF-I
diffusion and cell receptor signaling; (2) intra-cellular and
particularly nuclear IGFBP-3 may deliver independent sig-
nals to the gene activating machinery. An observation orig-
inating in this study is that matrix IGFBP-3 appears most
prominent in the top half of cartilage, particularly in normal
cartilage. Likewise, normal cartilage showed cellular stain
in the upper zones, but none was detectable in the deep
zone cells. Future studies will need to dissect the contribu-
tions of different autocrine and paracrine sources to IGFBP-
3 levels in the different tissue compartments. In addition to
the chondrocyte, both the synovial ﬂuid and underlying
bone could contribute signals; additionally mechanical fac-
tors may contribute to the autocrine or paracrine regulation
of this binding protein.
The association of immunoreactive IGFBP-3 with chon-
drocyte nuclei is consistent with the presence of a bipartite
nuclear localization sequence in the carboxyl terminal do-
main of this binding protein24. Indeed IGFBP-3 has been
shown to be transported to or to be present in the nucleus
of several cell lines25e28, and its nuclear presence has
been associated with the regulation of cell division and
apoptosis29e31. Few studies have been carried out on intact
tissue sections, but immunostaining of human colonic epi-
thelial sections revealed strong cytoplasmic and nuclear
IGFBP-3 in malignant and benign tumors compared to nor-
mal epithelium32. Recent studies suggest that endogenous
IGFBP-3 may exit the cell before it is re-internalized and
translocated to the nucleus30. The cellular uptake may
take place via the transferin receptor (a clathrin pathway)
and the caveolin routes27,28, and the nuclear uptake occurs
in association with the importin b subunit26. The regulation
of IGFBP-3 re-entry into the cell may depend on its ability
to bind IGF-I or additional posttranslational modiﬁcations27
but the precise mechanisms underlying this important dy-
namic remain under investigation. Importantly, it has been
shown that once in the nucleus, IGFBP-3 may have the abil-
ity to regulate gene expression, a case that has been well
illustrated with the retinoid receptor system, which regulates
apoptosis14,33. The case for nuclear regulatory actions of
IGFBP-3 has also been recently supported by the identiﬁca-
tion of a direct physical interaction between the binding pro-
tein and ribonucleic acid polymerase II binding subunit 334.
In summary, our study opens new avenues of exploration
into the role of IGFBP-3 at the level of gene activation in
cartilage and in human OA.Acknowledgements
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